scholarly journals Quality Assessment of Oral Anticoagulation by Time in Therapeutic Range in Patients with Venous Thromboembolism in Korea

2019 ◽  
Vol 5 (1) ◽  
pp. 8-10
Author(s):  
Hun-Gyu Hwang ◽  
Myung Shin Kim ◽  
Gune-Il Lim ◽  
So-My Koo ◽  
Bo Young Lee ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Quality Assessment ◽  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Time In Therapeutic Range

scholarly journals Quality of management of oral anticoagulation as assessed by time in therapeutic range in elderly and younger patients

2018 ◽  
Vol 10 (1) ◽  
pp. 80-81
Author(s):  
L. Laroussi ◽  
Z. Ibn Elhadj ◽  
M. Boukhris ◽  
O.N.S. Loukil ◽  
W. Ben Amara ◽  
...  
Keyword(s):  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Younger Patients ◽  
Time In Therapeutic Range

scholarly journals Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e42269 ◽  
Author(s):  
Petra M. G. Erkens ◽  
Hugo ten Cate ◽  
Harry R. Büller ◽  
Martin H. Prins
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Therapeutic Range ◽  
Meta Analysis ◽  
Time In Therapeutic Range

scholarly journals Elderly Disabled Patients in Oral Anticoagulation Treatment: An Evaluation of a Bioanalyst-Led Management Program Reaching an Average of 72% of Time in Therapeutic Range

2014 ◽  
Vol 04 (12) ◽  
pp. 623-630
Author(s):  
Thomas Vedtofte ◽  
Gitte Vedel Melsen ◽  
Lise Bathum ◽  
Christina Ellervik ◽  
Maja Jørgensen
Keyword(s):  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Management Program ◽  
Anticoagulation Treatment ◽  
Time In Therapeutic Range ◽  
Disabled Patients

scholarly journals Evaluation of Time in Therapeutic Range of Patients with Non-Valvular Atrial Fibrillation on Oral Anticoagulation with Vitamin K Antagonist in Delta Region

2021 ◽  
pp. 32-38
Author(s):  
Mohamed Kamel Abdel Aal ◽  
Mohamed Bayoumi Nassar ◽  
Abd El Latif El Gendy ◽  
Seham Fahmy Badr
Keyword(s):  
Atrial Fibrillation ◽  
Vitamin K ◽  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Statistical Significance ◽  
Significant Proportion ◽  
Vitamin K Antagonist ◽  
Delta Region ◽  
Time In Therapeutic Range ◽  
Percent Time

Background: Non-valvular atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence as high as 1.5±2.0% in the general population. This arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. The aim of study was to evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range. Patients and Methods: A total of 100 patients were included in this study for evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range. Results: Our study showed that only 35% achieved the recommended TTR (percent time in therapeutic range) above 60% from studied risk factors, none showed statistical significance. Conclusions: The quality of anticoagulant control was lower that reported in European countries with a significant proportion of patients had TTR below 60%.

scholarly journals Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine

2022 ◽  
Vol 14 (1) ◽  
pp. 37-38
Author(s):  
N. Lorenzo ◽  
R. Martín-Sánchez ◽  
M. Mendez-Bailon ◽  
A.E. Calvo-Elias ◽  
E. Calvo-Manuel ◽  
...  
Keyword(s):  
Internal Medicine ◽  
Heart Failure ◽  
Acute Heart Failure ◽  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Hospital Readmission ◽  
Clinical Impact ◽  
Time In Therapeutic Range

Sex‐influence on the time in therapeutic range (TTR) during oral anticoagulation with coumarin derivatives: systematic review and meta‐analysis

2021 ◽  
Author(s):  
Catiane Costa Viana ◽  
Marcus Fernando da Silva Praxedes ◽  
Waleska Jaclyn Freitas Nunes Sousa ◽  
Frederico Bartolazzi ◽  
Mayara Sousa Vianna ◽  
...  
Keyword(s):  
Systematic Review ◽  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Meta Analysis ◽  
Coumarin Derivatives ◽  
Sex Influence ◽  
Time In Therapeutic Range

scholarly journals 5743Clinical determinants of time in therapeutic range and the role of SAMe-TT2R2 score in atrial fibrillation patients receiving oral anticoagulation: data from FANTASIIA registry

2017 ◽  
Vol 38 (suppl_1) ◽  
Author(s):  
M.A. Esteve Pastor ◽  
I. Roldan Rabadan ◽  
J. Muniz ◽  
A. Cequier ◽  
V. Bertomeu-Martinez ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Time In Therapeutic Range

scholarly journals Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 365
Author(s):  
Rubén Ángel Martín-Sánchez ◽  
Noel Lorenzo-Villalba ◽  
Alberto Elpidio Calvo-Elías ◽  
Ester Emilia Dubón-Peralta ◽  
Cynthia Elisa Chocrón-Benbunan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Therapeutic Range ◽  
Oral Anticoagulation ◽  
Statistical Significance ◽  
International Normalized Ratio ◽  
Time In Therapeutic Range ◽  
Patients With Heart Failure ◽  
Hemorrhagic Events ◽  
Early Readmission ◽  
The Relationship

Background and objectives: Patients with heart failure (HF) often present with non-valvular atrial fibrillation and require oral anticoagulation with coumarin anticoagulants such as acenocoumarol. The objective of this study was to evaluate the relationship between time in therapeutic range (TTR) and the risk of early readmission. Materials and Methods: A retrospective descriptive study was carried out on hospitalized patients with a diagnosis of HF between 2014 and 2018 who had adverse effects due to oral anticoagulation with acenocoumarol (underdosing, overdosing, or hemorrhage). Clinical, analytical, therapeutic, and prognostic variables were collected. TTR is defined as the duration of time in which the patient’s International Normalized Ratio (INR) values were within a desired range. Early readmission was defined as readmission within 30 days after hospital discharge. Patients were divided into two groups depending on whether or not they had a TTR less than 60% (TTR < 60%) over the 6 months prior to the adverse event. Results: In the cohort of 304 patients, the mean age was 82 years, 59.9% of the patients were female, and 54.6% had a TTR < 60%. Patients with TTR < 60% had a higher HAS-BLED score (4.04 vs. 2.59; p < 0.001) and INR (6 vs. 5.31; p < 0.05) but lower hemoglobin (11.67 vs. 12.22 g/dL; p < 0.05). TTR < 60% was associated with early readmission after multivariate analysis (OR: 2.05 (CI 95%: 1.16–3.61)). They also had a higher percentage of hemorrhagic events and in-hospital mortality but without reaching statistical significance. Conclusions: Patients with HF and adverse events due to acenocoumarol often have poor INR control, which is independently associated with a higher risk of early readmission.

Sign in / Sign up

Export Citation Format

Share Document